Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure
- PMID: 27140986
- DOI: 10.1377/hlthaff.2015.1145
Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure
Abstract
The cost of treating cancer has risen to unprecedented heights, putting tremendous financial pressure on patients, payers, and society. Previous studies have documented the rising prices of cancer drugs at launch, but less critical attention has been paid to the cost of these drugs after launch. We used pharmacy claims for commercially insured individuals to examine trends in postlaunch prices over time for orally administered anticancer drugs recently approved by the Food and Drug Administration (FDA). In the period 2007-13, inflation-adjusted per patient monthly drug prices increased 5 percent each year. Certain market changes also played a role, with prices rising an additional 10 percent with each supplemental indication approved by the FDA and declining 2 percent with the FDA's approval of a competitor drug. Our findings suggest that there is currently little competitive pressure in the oral anticancer drug market. Policy makers who wish to reduce the costs of anticancer drugs should consider implementing policies that affect prices not only at launch but also later.
Keywords: Cost of Health Care; Employer-Based System < Insurance; Health Economics; Pharmaceuticals; oncology.
Project HOPE—The People-to-People Health Foundation, Inc.
Similar articles
-
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.JAMA Oncol. 2021 Sep 1;7(9):e212026. doi: 10.1001/jamaoncol.2021.2026. Epub 2021 Sep 16. JAMA Oncol. 2021. PMID: 34196656 Free PMC article.
-
What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.Issue Brief (Commonw Fund). 2018 Apr 1;2018:1-10. Issue Brief (Commonw Fund). 2018. PMID: 29992802
-
Trajectories of Injectable Cancer Drug Costs After Launch in the United States.J Clin Oncol. 2018 Feb 1;36(4):319-325. doi: 10.1200/JCO.2016.72.2124. Epub 2017 Oct 10. J Clin Oncol. 2018. PMID: 29016226
-
The high price of anticancer drugs: origins, implications, barriers, solutions.Nat Rev Clin Oncol. 2017 Jun;14(6):381-390. doi: 10.1038/nrclinonc.2017.31. Epub 2017 Mar 14. Nat Rev Clin Oncol. 2017. PMID: 28290490 Review.
-
Hospital pricing: cost shifting and competition.EBRI Issue Brief. 1993 May;(137):1-17. EBRI Issue Brief. 1993. PMID: 10129621 Review.
Cited by
-
Oncologic drug repository programs in the United States: a review and comparison.Health Aff Sch. 2024 Mar 6;2(3):qxae031. doi: 10.1093/haschl/qxae031. eCollection 2024 Mar. Health Aff Sch. 2024. PMID: 38756923 Free PMC article.
-
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.Pharmacoeconomics. 2024 Jan;42(1):117-131. doi: 10.1007/s40273-023-01320-4. Epub 2023 Oct 19. Pharmacoeconomics. 2024. PMID: 37855850 Free PMC article.
-
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers.Ther Adv Drug Saf. 2023 Aug 24;14:20420986231188845. doi: 10.1177/20420986231188845. eCollection 2023. Ther Adv Drug Saf. 2023. PMID: 37636837 Free PMC article.
-
Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy.J Clin Oncol. 2023 Jan 10;41(2):170-172. doi: 10.1200/JCO.22.01711. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265102 Free PMC article. No abstract available.
-
Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer.JCO Oncol Pract. 2022 Nov;18(11):e1739-e1749. doi: 10.1200/OP.22.00171. Epub 2022 Sep 13. JCO Oncol Pract. 2022. PMID: 36099549 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources